Use of amylin agonists in the treatment of diabetes mellitus

Details Use of amylin agonists in the treatment of diabetes mellitus Use of amylin agonists in the treatment of diabetes mellitus

C - Chemistry, Metallurgy

07

K

167/122, 150/9,

C07K 14/575 (2006.01) A61K 38/22 (2006.01) A61K 38/28 (2006.01) G01N 33/53 (2006.01) A61K 38/00 (2006.01)

Patent

CA 1341060

Peptides amylin (provisionally named diabetes associated peptide or DAP), carboxy terminally amidated amylin (amylin-NH2) and calcitonin gene related peptide (CGRP) or active fragments thereof are useful for the treatment of diabetes mellitus or hypoglycaemia. The peptides may be used together with insulin and conveniently administered parenterally in tree form of solution.

575792

Affiliated with

Also associated with

Rating

Use of amylin agonists in the treatment of diabetes mellitus does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of amylin agonists in the treatment of diabetes mellitus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of amylin agonists in the treatment of diabetes mellitus will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1259044